Canaccord cuts ResMed price target 11% to A$35.61

Canaccord Genuity lowered its price target on ResMed by 11% to A$35.61 a share. The note carried no stated rating change or rationale in the material available. The target is denominated in Australian dollars, so it applies to the ASX-quoted line rather than the primary US listing, though the view still reads across to the US-listed shares.